Novo Nordisk’s 2026 Q2 Call: R&D Spending and Pipeline Risk Signals Don’t Match

Date of Call: Aug 5, 2026

Business Commentary:

R&D and Pipeline Strategy:

• The company is actively searching for new business development opportunities to complement its existing pipeline, focusing on areas like glucagon and sickle cell disease therapies.
• This strategy is driven by a balance between high-value and low-risk projects and higher-risk, high-value projects to ensure a diversified portfolio capable of generating significant value.

Recent Success in Sickle Cell Disease:

• The announcement of Mopivet Phase III data is considered groundbreaking in sickle cell disease, with plans for regulatory submission very soon.
• The success in this area is supported by positive data that aligns with the company's risk assessment, acknowledging that certain high-risk projects like silicevacumab involve uncertainties regarding biomarker correlations.

Risk Management in Drug Development:

• The company acknowledges the inherent risks in R&D and drug development, particularly in high-risk projects where biomarkers may not correlate directly with outcomes.
• Efforts to mitigate these risks involve a deep understanding of the disease areas, pathophysiology, and pharmacology to improve the risk profile of their projects.

Sentiment Analysis:

Overall Tone: Positive

• Management highlights positive Phase III data for Mopivet in sickle cell disease, calling it 'among the most groundbreaking... that we've seen for many years' and aims for 'regulatory submission of that data... very, very soon.' They also state the pipeline balances 'high value, reasonably low risk' with 'higher risk, but equally higher value' projects, indicating a strong strategic position.

Q&A:

• Question from Mike: Concerns about R&D risk and drug development.
  Response: Management acknowledges risk but cites recent positive Phase III data as a success and emphasizes a balanced pipeline with both low and higher-risk projects to generate value.

Contradiction Point 1

R&D Investment Strategy and Cadence

Contradiction on the expected level of R&D investment in the near term.

Mike - Mike

2026Q2: The pipeline balances high-value, reasonably low-risk projects with higher-risk, higher-value projects. - Martin(Responder's Name)

How does the recent positive Phase III data for Mopivet influence the risk profile of the R&D pipeline? - Simon Baker (Rothschild & Co.)

2026Q1: R&D investment is a strategic priority to expand the pipeline. Q1 R&D was on the low side for the year; the company expects to lean in on R&D investment in coming quarters. - Karsten Munk Knudsen(CFO)

Contradiction Point 2

Pipeline Project Risk Characterization

Contradiction in describing the risk profile of specific pipeline assets.

Mike - Mike

2026Q2: The pipeline balances high-value, reasonably low-risk projects with higher-risk, higher-value projects. The recent positive Phase III data for Mopivet... is a success... - Martin(Responder's Name)

How does the recent positive Phase III data for Mopivet impact the risk profile of the R&D pipeline? - Michael Nedelcovych (TD Cowen)

2026Q1: Trials ZEUS (ASCVD), HERMES (heart failure with preserved ejection fraction), and ARTEMIS (post-MI) represent high-potential indications for ciltavecumab, but they are also high-risk until first data is seen. - Martin Holst Lange(Chief Scientific Officer)

Contradiction Point 3

R&D Pipeline Risk Profile and Strategy

The characterization of the pipeline's risk balance appears inconsistent.

Mike - Mike

2026Q2: The pipeline balances high-value, reasonably low-risk projects with higher-risk, higher-value projects. - Martin(EVP, R&D)

How does the recent positive Phase III data for Mopivet impact the overall risk profile of the R&D pipeline? - Peter Verdult (BNP Paribas)

2025Q4: The guidance is based on dynamic market trends and the latest available data... The range accounts for uncertainties in a rapidly changing market. - Martin Holst Lange(EVP, R&D, CSO) & Mike Doustdar(CEO)

Contradiction Point 4

Business Development and Pipeline Complement Strategy

The level of detail and specificity regarding business development plans has shifted.

Mike - Mike

2026Q2: The company is evaluating therapy areas and modalities... It is also exploring business development opportunities to complement its pipeline. More details will be shared at the upcoming Capital Market Day. - Martin(EVP, R&D)

Which therapy areas align with the company's scientific and commercial strengths, and how can business development support these areas? - Peter Verdult (BNP Paribas)

2025Q4: The guidance... is based on dynamic market trends and the latest available data (including strong Wegovy pill uptake data). - Martin Holst Lange(EVP, R&D, CSO) & Mike Doustdar(CEO)

Contradiction Point 5

R&D Pipeline Risk Profile

Inconsistent characterization of pipeline risk, shifting from balanced to high-risk emphasis.

Mike - Mike

2026Q2: The pipeline balances high-value, reasonably low-risk projects with higher-risk, higher-value projects. - Martin(Responding Executive)

How does the recent positive Phase III data for Mopivet impact the risk profile of the R&D pipeline? - Carsten Lomberg-Madsen (Danske Bank)

2025Q3: The CEO acknowledged the loss [of market share] but emphasized that the company's focus is on expanding the overall... markets... Initiatives include launching new products... and intensifying commercial efforts. - Mike Duster(CEO)